Advance Search
ZHAO Xiaoya, TANG Xiaowei, XIAO Wenhuan, DONG Wei. Effect of repetitive transcranial magnetic stimulation combined with amisulpride in treatment of schizophrenia and its influence on cognitive function[J]. Journal of Clinical Medicine in Practice, 2022, 26(23): 89-91, 96. DOI: 10.7619/jcmp.20222325
Citation: ZHAO Xiaoya, TANG Xiaowei, XIAO Wenhuan, DONG Wei. Effect of repetitive transcranial magnetic stimulation combined with amisulpride in treatment of schizophrenia and its influence on cognitive function[J]. Journal of Clinical Medicine in Practice, 2022, 26(23): 89-91, 96. DOI: 10.7619/jcmp.20222325
shu

Effect of repetitive transcranial magnetic stimulation combined with amisulpride in treatment of schizophrenia and its influence on cognitive function

  • Wutaishan Hospital of Jiangsu Province, Yangzhou, Jiangsu, 225003

More Information
  • Received Date: July 28, 2022
  • Available Online: December 22, 2022
    Graphical Abstract
    • Abstract
  • Objective 

    To observe the effect of repetitive transcranial magnetic stimulation (rTMS) combined with amisulpride in the treatment of schizophrenia and its influence on cognitive function.

    Methods 

    A total of 100 schizophrenia patients were enrolled as study objects, and they were randomly divided into study group and control group, with 50 patients in each group. The control group was treated with amsulpiride, and the study group was treated with amsulpiride combined with rTMS. The clinical symptom score, therapeutic effect and cognitive function score of the two groups were compared.

    Results 

    Before treatment, there was no significant difference in clinical symptom score between the two groups (P>0.05). After treatment, the general psychopathological score, positive symptom score, and negative symptom score of the study group were(30.13±1.23), (12.31±2.01), (17.91±4.15), which were lower than (33.17±2.15), (14.31±1.33), (20.31±3.17), respectively in the control group (P < 0.05). The total effective rate of the study group was 96.00% (48/50), which was higher than 68.00% (34/50) of the control group, and the difference was statistically significant (P < 0.05). Before treatment, there was no significant difference in cognitive function score between the two groups (P>0.05). After treatment, the item scores of all dimensions of cognitive function and total score in the study group were higher than those in the control group, and the differences were statistically significant (P < 0.05 or P < 0.01).

    Conclusion 

    In the treatment of schizophrenia patients, rTMS combined with amisulpride can improve cognitive function and therapeutic effect, and relieve mental symptoms compared with amisulpride treatment alone.

    • FullText(HTML)
    • References (19)
  • [1]
    钟远惠, 何晓华, 林壮国, 等. 氨磺必利联合奥氮平治疗慢性精神分裂症的疗效观察[J]. 广东药科大学学报, 2020, 36(2): 271-273. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYX202002022.htm
    [2]
    张玥, 唐小伟, 肖文焕, 等. 血清表皮生长因子和C反应蛋白与精神分裂症患者认知功能的关系[J]. 实用临床医药杂志, 2022, 26(11): 76-80, 86. doi: 10.7619/jcmp.20215055
    [3]
    KAHN R S, KEEFE R S. Schizophrenia is a cognitive illness: time for a change in focus[J]. JAMA Psychiatry, 2013, 70(10): 1107-1112. doi: 10.1001/jamapsychiatry.2013.155
    [4]
    唐小伟, 耿德勤, 沙维伟, 等. 缺陷型精神分裂症患者认知功能的研究[J]. 实用临床医药杂志, 2013, 17(11): 59-61. doi: 10.7619/jcmp.201311019
    [5]
    巫彩莲, 吴晓雄, 郁缪宇. 重复经颅磁刺激治疗精神疾病临床研究进展[J]. 临床精神医学杂志, 2022, 32(3): 243-245. https://www.cnki.com.cn/Article/CJFDTOTAL-LCJS202203020.htm
    [6]
    张保华, 谭云龙, 张五芳, 等. 重复性成套神经心理状态测验的信度、效度分析[J]. 中国心理卫生杂志, 2008, 22(12): 865-869. doi: 10.3321/j.issn:1000-6729.2008.12.001
    [7]
    GRYNSZPAN O, PERBAL S, PELISSOLO A, et al. Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a meta-analytical study[J]. Psychol Med, 2011, 41(1): 163-173. doi: 10.1017/S0033291710000607
    [8]
    宫雪. 氨磺必利与氯氮平治疗阴性症状为主精神分裂症患者临床疗效的对比观察[J]. 医学理论与实践, 2020, 33(4): 571-573. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLL202004023.htm
    [9]
    郗玲燕, 金圭星, 张素允, 等. 齐拉西酮联合氯丙嗪治疗老年精神分裂症患者的疗效分析[J]. 实用临床医药杂志, 2021, 25(16): 116-119. doi: 10.7619/jcmp.20211029
    [10]
    张志勇, 原富强, 程德君. 奥氮平联合氨磺必利治疗精神分裂症的效果及其对睡眠和认知功能的影响[J]. 国际精神病学杂志, 2020, 47(1): 43-45, 57. https://www.cnki.com.cn/Article/CJFDTOTAL-GWYJ202001013.htm
    [11]
    吴涛, 彭智勇, 刘龙平. 氨磺必利联合奥氮平治疗精神分裂症患者的临床效果[J]. 医疗装备, 2020, 33(3): 87-88. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZB202003048.htm
    [12]
    金学敏. 温胆汤联合氨磺必利治疗难治性精神分裂症患者的疗效[J]. 医疗装备, 2019, 32(24): 132-133. https://www.cnki.com.cn/Article/CJFDTOTAL-YLZB201924089.htm
    [13]
    俞萍, 肖文焕, 赵义林, 等. 氨磺必利对青少年精神分裂症患者社会功能和神经认知的影响[J]. 实用临床医药杂志, 2021, 25(22): 67-70. doi: 10.7619/jcmp.20211561
    [14]
    孙来顺. 精神分裂症的药物治疗[J]. 医学信息, 2021, 34(21): 42-45. https://www.cnki.com.cn/Article/CJFDTOTAL-YXXX202121010.htm
    [15]
    ZHUO K, WANG Y, SONG Z, et al. Effects of rTMS on cognitive and negitive symptoms of schizophrenia: A randomized double-blind sham-controlled study[J]. Eur Psychiatry, 2016, 33: S335-S335.
    [16]
    穆小梅, 王秀梅, 牛慧明, 等. 奥氮平与氨磺必利联合用药方案治疗难治性精神分裂症的临床价值评价[J]. 中国全科医学, 2019, 22(S2): 258-259. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX2019S2091.htm
    [17]
    陈敏梅, 黎海雁, 蔡守彬, 等. 氨磺必利联合氯氮平治疗慢性精神分裂症的疗效及对血清泌乳素、认知功能的影响[J]. 中国处方药, 2019, 17(12): 84-85. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCF201912050.htm
    [18]
    QUINTERO J, BARBUDO E, MOLINA J D, et al. The effectiveness of the combination therapy of amisulpride and quetiapine for managing treatment-resistant schizophrenia: a naturalistic study[J]. J Clin Psychopharmacol, 2011, 31(2): 240-242.
    [19]
    朱玉华, 朱丽萍, 吴海苏. 精神分裂症认知功能障碍的病因研究进展[J]. 精神医学杂志, 2010, 23(4): 303-305. https://www.cnki.com.cn/Article/CJFDTOTAL-SDJB201004032.htm
    • Related Articles

  • Related Articles

    [1]XUE Jing, XIAO Wenhuan, YAO Jing, ZHANG Jun. Effects of lurasidone on efficacy and cognitive function of patients with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 57-60. DOI: 10.7619/jcmp.20231119
    [2]LIU Wei, GENG Jundi, JIA Huizhen, WANG Xiao. Correlations of serum c-Jun N-terminal kinase expression with cognitive function and prognosis in patients with first-episode schizophrenia[J]. Journal of Clinical Medicine in Practice, 2023, 27(8): 48-54. DOI: 10.7619/jcmp.20223465
    [3]XU Ying, XIAO Wenhuan, ZHAO Yilin, YANG Xiang, ZHONG Yunian. Relationship between cognitive function and fibroblast growth factor-2 in patients with schizophrenia and its gender difference[J]. Journal of Clinical Medicine in Practice, 2022, 26(14): 64-69. DOI: 10.7619/jcmp.20220046
    [4]ZHANG Yue, TANG Xiaowei, XIAO Wenhuan, ZHAO Xiaoya. Correlations of serum epidermal growth factor and C-reactive protein with cognitive function in patients with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2022, 26(11): 76-80, 86. DOI: 10.7619/jcmp.20215055
    [5]YU Ping, XIAO Wenhuan, ZHAO Yilin, ZHAO Xiaoya. Effect of amisulpride on social function and neurocognition of adolescents with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2021, 25(22): 67-70. DOI: 10.7619/jcmp.20211561
    [6]LI Yifan, WANG Jian, JIN Yuyan, SHAO Yi, TONG Yujie, LIU Zhihui. Effect of etomidate combined with propofol on stressresponse and cognitive function in schizophrenia patients with modified electric convulsive therapy[J]. Journal of Clinical Medicine in Practice, 2019, 23(13): 42-45. DOI: 10.7619/jcmp.201913012
    [7]LIU Ying. Effect of active psychological support combined with stratified nursing in elderly patients with schizophrenia[J]. Journal of Clinical Medicine in Practice, 2019, 23(8): 108-110, 114. DOI: 10.7619/jcmp.201908030
    [8]XU Qiong, MEI Shuangyan. The effect of antipsychotic drugs combined with psychological intervention on cognitive and social function in schizophrenic patients[J]. Journal of Clinical Medicine in Practice, 2015, (10): 99-101. DOI: 10.7619/jcmp.201510031
    [9]TANG Xiaowei, GEN Deqin, SHA Weiwei, ZHANG Xiaobin, ZHOU Chaoyun. Research of cognitive function in deficit schizophrenia[J]. Journal of Clinical Medicine in Practice, 2013, (11): 59-61. DOI: 10.7619/jcmp.201311019
    [10]ZHAO Yi-lin, SUN Jin-rong, CHENG Zao-huo, SHA Wei-wei, ZHANG Xiao-bin, DIN Zhao-sheng, BU Ru. Cognitive function and its related factors in schizophrenia[J]. Journal of Clinical Medicine in Practice, 2009, (19): 9-11. DOI: 10.3969/j.issn.1672-2353.2009.19.004

  • Cited by

    Periodical cited type(11)

    1. 张桂艳，杨勇锋，程德君. 氨磺必利联合无抽搐电休克治疗对精神分裂症患者心电图的影响. 医药论坛杂志. 2024(02): 182-185+190 .
    2. 徐瑞华，王幸，黄小振. 氨磺必利与利培酮治疗男性精神分裂症的效果比较. 中国实用医刊. 2024(06): 109-112 .
    3. 张小娟，陈正. 氨磺必利联合重复经颅磁刺激治疗对精神分裂症后抑郁伴自杀倾向患者社会功能及心理健康的影响. 系统医学. 2024(07): 23-27 .
    4. 余芬，贾舒祺，王芃，李淑璠，王兴. 重复经颅磁刺激对精神分裂症患者认知功能干预效果的meta分析. 中国心理卫生杂志. 2024(09): 745-751 .
    5. 刘旭东. 经颅磁刺激联合药物干预在难治性精神分裂症患者中的治疗效果及对事件相关电位和认知功能的影响研究. 系统医学. 2024(15): 25-28+51 .
    6. 蒋洪宾，季磊，陶传斌. 氨磺必利结合重复经颅磁刺激治疗对精神分裂症后抑郁伴自杀倾向患者的影响研究. 心理月刊. 2024(22): 99-101 .
    7. 郭晶，高翔，李艳. 丁螺环酮联合氨磺必利治疗精神分裂症阴性症状的临床效果. 临床合理用药. 2024(35): 51-54 .
    8. 葛玉巧，董光举. 氨磺必利联合奥氮平对难治性精神分裂症的疗效观察. 实用中西医结合临床. 2023(08): 50-52 .
    9. 李彤. 英智脉冲磁场刺激仪M-50 Ultimate实施重复经颅磁刺激治疗精神分裂症的效果. 中国医疗器械信息. 2023(12): 131-133 .
    10. 顾芸，杨晓龙. 重复经颅磁刺激联合常规药物治疗老年精神分裂症患者的效果. 中国民康医学. 2023(20): 102-105 .
    11. 武莹莹. 小剂量氨磺必利联合利培酮治疗精神分裂症康复期女性患者的临床效果. 妇儿健康导刊. 2023(20): 114-116 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (169) PDF downloads (10) Cited by(12)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return